Autonomix Medical Inc., a development stage medical device company, has released its annual report for the fiscal year ending March 31, 2025. The company is focused on advancing technologies for sensing and treating nervous system disorders, with an initial focus on patients with pancreatic cancer. The report indicates that Autonomix Medical is in the research and development phase and has not yet achieved regulatory approval or commercialization of its device, which means it has not generated revenue from sales. The company's operating expenses are classified into three categories: research and development, general and administrative, and warrant expense - termination agreement. Research and development expenses are primarily driven by costs associated with animal research, design and development of technology, and salaries for employees engaged in these activities. Autonomix Medical highlights the uncertainties involved in obtaining necessary regulatory approvals and the commercialization process, indicating that the duration and costs of their research and development are currently undetermined. No specific financial outlook or guidance for future sales or revenue generation has been provided. The report emphasizes the company's focus on advancing its innovative technology platform for detecting and differentiating neural signals, with potential applications beyond pancreatic cancer in the future.